Hypertension Research

Journal Information
ISSN / EISSN : 0916-9636 / 1348-4214
Published by: Springer Nature (10.1038)
Total articles ≅ 4,266
Current Coverage
SCOPUS
SCIE
MEDICUS
MEDLINE
PUBMED
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Kazuomi Kario, Naoko Tomitani, Tomoko Morimoto, Hiroshi Kanegae, Peter Lacy, Bryan Williams
Published: 17 October 2021
Hypertension Research pp 1-10; https://doi.org/10.1038/s41440-021-00758-3

The publisher has not yet granted permission to display this abstract.
Keisuke Narita, Satoshi Hoshide, Kazuomi Kario
Published: 17 October 2021
Hypertension Research pp 1-12; https://doi.org/10.1038/s41440-021-00757-4

The publisher has not yet granted permission to display this abstract.
Hironori Nakagami, Tetsuya Ishihama, Yuichi Daikyoji, Chieka Sasakura, Ei Yamada, Ryuichi Morishita
Published: 17 October 2021
Hypertension Research pp 1-5; https://doi.org/10.1038/s41440-021-00755-6

Abstract:
We have been developing an angiotensin II vaccine for hypertension. We conducted a placebo-controlled dose escalation study to investigate the safety, tolerability, and immunological responses of this angiotensin II vaccine (AGMG0201). AGMG0201 was administered to participants with mild to moderate hypertension between 18 and 79 years of age. Twelve patients each were enrolled in the low-dose and high-dose groups. Within each group, subjects were randomly assigned to receive either the active study drug or a placebo at a ratio of 3:1. Each participant received a single intramuscular injection, followed by a second injection 30 days later, and was monitored for 360 days after the second dose. The results showed that most treatment-related adverse events were classified as mild or moderate in severity, including pain and erythema at the injection site. Anti-angiotensin II antibodies were observed in the AGMG0201 patients, especially in the high-dose group. Overall, AGMG0201 was well tolerated.
Kenya Kusunose, Hisako Yoshida, Atsushi Tanaka, Hiroki Teragawa, Yuichi Akasaki, Yoshihiro Fukumoto, Kazuo Eguchi, Haruo Kamiya, Kazuomi Kario, Hirotsugu Yamada, et al.
Published: 17 October 2021
Hypertension Research pp 1-10; https://doi.org/10.1038/s41440-021-00752-9

Abstract:
Hyperuricemia is related to an increased risk of cardiovascular events from a meta-analysis and antihyperuricemia agents may influence to cardiac function. We evaluated the effect of febuxostat on echocardiographic parameters of diastolic function in patients with asymptomatic hyperuricemia as a prespecified endpoint in the subanalysis of the PRIZE study. Patients in the PRIZE study were assigned randomly to either add-on febuxostat treatment group or control group with only appropriate lifestyle modification. Of the 514 patients in the overall study, 65 patients (31 in the febuxostat group and 34 in the control group) who had complete follow-up echocardiographic data of the ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e′) at baseline and after 12 and 24 months were included. The primary endpoint was a comparison of the changes in the E/e′ between the two groups from baseline to 24 months. Interestingly, e′ was slightly decreased in the control group compared with in the febuxostat group (treatment p = 0.068, time, p = 0.337, treatment × Time, p = 0.217). As a result, there were significant increases in E/e′ (treatment p = 0.045, time, p = 0.177, treatment × time, p = 0.137) after 24 months in the control group compared with the febuxostat group. There was no significant difference in the serum levels of N-terminal-pro brain natriuretic peptide and high-sensitive troponin I between the two groups during the study period. In conclusions, additional febuxostat treatment in patients with asymptomatic hyperuricemia for 24 months might have a potential of preventable effects on the impaired diastolic dysfunction.
Yukako Ogoyama, Kazuhiro Tada, Makiko Abe, Shinsuke Nanto, Hirotaka Shibata, Masashi Mukoyama, Hisashi Kai, Hisatomi Arima, Kazuomi Kario
Published: 17 October 2021
Hypertension Research pp 1-11; https://doi.org/10.1038/s41440-021-00761-8

The publisher has not yet granted permission to display this abstract.
Kazuomi Kario, Hideaki Kagitani, Shoko Hayashi, Satsuki Hanamura, Keisuke Ozawa, Hiroshi Kanegae
Published: 17 October 2021
Hypertension Research pp 1-9; https://doi.org/10.1038/s41440-021-00760-9

Abstract:
Renal denervation is a potential alternative to antihypertensive drug therapy. However, data on patient preference for this treatment option are limited and there are no data specifically from Asian patients. This study evaluated patient preference for renal denervation in patients with hypertension from Japan. Patients were a subset of those who participated in a March 2020 online electronic survey of patients with hypertension who had regularly visited medical institutions for treatment, were receiving antihypertensive drug therapy and had home blood pressure recordings available. The survey included a question about patient preference for treatment with renal denervation. A total of 2,392 patients were included (66% male, mean age 59.8 ± 11.6 years, mean duration of hypertension 11.4 ± 9.5 years). Preference for renal denervation was expressed by 755 patients (31.6%), and was higher in males than in females, in younger compared with older patients, in those with higher versus lower blood pressure, in patients who were less adherent versus more adherent to antihypertensive drug therapy, and in those who did rather than did not have antihypertensive drug-related side effects. Significant predictors of preference for renal denervation on logistic regression analysis were younger patient age, male sex, higher home or office systolic blood pressure, poor antihypertensive drug adherence, the presence of heart failure, and the presence of side effects during treatment with antihypertensive drugs. Overall, a relevant proportion of Japanese patients with hypertension expressed a preference for renal denervation. This should be taken into account when making shared decisions about antihypertensive drug therapy.
Back to Top Top